376 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Whipplewood Advisors LLC

Whipplewood Advisors LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 376 shares of the biopharmaceutical company’s stock, valued at approximately $35,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. NewEdge Wealth LLC boosted its holdings in Gilead Sciences by 8.1% in the 4th quarter. NewEdge Wealth LLC now owns 404,817 shares of the biopharmaceutical company’s stock worth $37,393,000 after buying an additional 30,243 shares during the period. Simmons Bank boosted its holdings in shares of Gilead Sciences by 1.0% in the fourth quarter. Simmons Bank now owns 40,058 shares of the biopharmaceutical company’s stock worth $3,700,000 after acquiring an additional 394 shares during the period. Checchi Capital Advisers LLC grew its position in shares of Gilead Sciences by 2.9% in the fourth quarter. Checchi Capital Advisers LLC now owns 10,565 shares of the biopharmaceutical company’s stock valued at $976,000 after purchasing an additional 297 shares in the last quarter. National Pension Service raised its stake in shares of Gilead Sciences by 15.8% during the 4th quarter. National Pension Service now owns 3,250,202 shares of the biopharmaceutical company’s stock valued at $300,221,000 after purchasing an additional 442,559 shares during the period. Finally, Advisor OS LLC lifted its holdings in Gilead Sciences by 12.4% during the 4th quarter. Advisor OS LLC now owns 5,137 shares of the biopharmaceutical company’s stock worth $474,000 after purchasing an additional 566 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 2.1 %

Shares of GILD stock opened at $114.31 on Friday. The business has a 50-day moving average of $97.42 and a 200 day moving average of $90.05. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $114.77. The stock has a market capitalization of $142.46 billion, a PE ratio of 308.95, a P/E/G ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.76%. Gilead Sciences’s payout ratio is presently 854.05%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders sold 293,356 shares of company stock valued at $29,166,240. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on GILD shares. Wolfe Research initiated coverage on Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 price target on the stock. Robert W. Baird increased their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. Finally, Wells Fargo & Company boosted their target price on Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.